Want to see IN:NURECA full AI Analyst Report?
Top Page
Nureca Ltd.
(NURECA)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹338.00
▲(13.10% Upside)
Action:Reiterated
Date:07/15/26
The score is held back primarily by expensive valuation (very high P/E) and inconsistent/weak cash-flow conversion despite recent improvement. Offsetting this is a strong, low-leverage balance sheet and an improving revenue/profitability trend, while technicals show an uptrend but with stretched momentum signals.
Positive Factors
Revenue recovery and growth
The return to revenue growth suggests improving product demand and market reach after a period of contraction. Sustained recovery across the home healthcare portfolio could support operating scale and strengthen the company’s competitive position.
Negative Factors
Thin and reduced operating margins
Low margins leave limited protection against product costs, marketplace fees, discounts, logistics expenses or returns. The sharp decline from earlier profitability also indicates that stronger revenue alone may not translate into durable earnings without better pricing or cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue recovery and growth
The return to revenue growth suggests improving product demand and market reach after a period of contraction. Sustained recovery across the home healthcare portfolio could support operating scale and strengthen the company’s competitive position.
Read all positive factors
Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.19B
Dividend YieldN/A
Average Volume (3M)2.25K
Price to Earnings (P/E)80.7
Beta (1Y)1.26
Revenue Growth23.92%
EPS GrowthN/A
CountryIN
Employees154
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)4.12
Shares Outstanding9,541,920
10 Day Avg. Volume1,493
30 Day Avg. Volume2,249
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)1.13
Price to Sales (P/S)1.39
P/FCF Ratio116.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nureca Ltd. Business Overview & Revenue Model
Company Description
Operating in India, Nureca Limited is a business-to-consumer (B2C) firm specializing in home healthcare and general wellness solutions. Their extensive product portfolio addresses various health needs, encompassing items for managing chronic condi...
How the Company Makes Money
Nureca makes money primarily by selling home healthcare and wellness products under its owned brands (notably Dr Trust and Dr Physio). Revenue is generated from (1) direct product sales to end consumers through the company’s own online storefronts...
Nureca Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
84
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.53B | 1.47B | 1.10B | 919.28M | 1.11B | 2.56B |
| Gross Profit | 388.35M | 352.34M | 231.33M | 311.42M | 355.94M | 1.23B |
| EBITDA | 115.10M | 85.19M | 48.95M | 2.41M | -79.04M | 632.04M |
| Net Income | 43.37M | 20.82M | 8.46M | -17.94M | -82.50M | 449.60M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.96B | 2.10B | 2.05B | 2.07B | 2.19B |
| Cash, Cash Equivalents and Short-Term Investments | 130.23M | 424.31M | 736.29M | 1.44B | 1.02B | 927.10M |
| Total Debt | 0.00 | 22.59M | 49.66M | 25.16M | 33.27M | 44.05M |
| Total Liabilities | -1.81B | 153.96M | 156.91M | 120.54M | 116.97M | 159.32M |
| Stockholders Equity | 1.81B | 1.81B | 1.94B | 1.93B | 1.95B | 2.03B |
Cash Flow | ||||||
| Free Cash Flow | -10.02M | 17.45M | -234.06M | -37.98M | 98.31M | -46.00M |
| Operating Cash Flow | 44.46M | 85.74M | -190.83M | -27.12M | 102.27M | 13.99M |
| Investing Cash Flow | -67.25M | 81.20M | 84.39M | 175.76M | -164.56M | -30.89M |
| Financing Cash Flow | 2.16M | -184.66M | -1.69M | -13.03M | -15.07M | -73.02M |
Nureca Ltd. Technical Analysis
Positive
298.85
Price Trends
295.68
Positive
277.16
Positive
277.40
Positive
Market Momentum
7.04
Positive
56.86
Neutral
77.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Positive. The current price of 298.85 is below the 20-day moving average (MA) of 327.50, above the 50-day MA of 295.68, and above the 200-day MA of 277.40, indicating a bullish trend. The MACD of 7.04 indicates Positive momentum. The RSI at 56.86 is Neutral, neither overbought nor oversold. The STOCH value of 77.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NURECA.
Nureca Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹14.67B | 27.17 | ― | 0.68% | 10.68% | -1.04% | |
74 Outperform | ₹109.93B | 42.73 | ― | 0.22% | -27.51% | -34.49% | |
68 Neutral | ₹94.27B | 29.23 | ― | 3.28% | 13.04% | 4.60% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹3.19B | 80.73 | ― | ― | 23.92% | ― | |
46 Neutral | ₹32.70B | -35.13 | ― | 0.06% | 78.89% | -50.29% |
* General Sector Average
IN:NURECA
Nureca Ltd.
334.00
75.05
28.98%
IN:AMRUTANJAN
Amrutanjan Health Care Limited
507.20
-219.57
-30.21%
IN:BLUEJET
Blue Jet Healthcare Limited
579.15
-128.41
-18.15%
IN:PGHL
Procter & Gamble Health Ltd.
5,762.20
-460.72
-7.40%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,214.10
-906.88
-17.71%
IN:ZOTA
Zota Health Care Ltd.
1,101.20
-223.98
-16.90%
Nureca Ltd. Corporate Events
Nureca Releases Q1 and FY 2027 Investor Presentation on Consumer Healthcare Platform Progress
Jul 21, 2026
Nureca Ltd. has released an investor presentation for the first quarter and full financial year 2027, following the submission of its unaudited standalone and consolidated results for the quarter ended June 30, 2026 to the stock exchanges. The pre...
Nureca Voluntarily Discloses Promoter Group Off-Market Share Sale
Jun 9, 2026
Nureca Limited has disclosed that Nectar Biopharma Private Limited, a member of its promoter group, has disposed of 60,842 equity shares of the company, representing 0.63% of its share capital, via an off-market transaction. Although recent SEBI c...
Nureca Publishes FY26 Audited Results in Line with Listing Norms
May 30, 2026
Nureca Limited has published its audited financial results for the quarter and year ended 31 March 2026 in leading newspapers, in line with regulatory disclosure requirements. The results were carried in a national English daily and a regional Mar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.